Meeting
2018 Genitourinary Cancers Symposium
Overall survival and treatment patterns among real-world patients with locally advanced or metastatic urothelial carcinoma treated with first-line therapy.
Authors
Jason C Simeone
Evidera, Waltham, MA
Jason C Simeone , Beth L Nordstrom , Ketan Patel , Alyssa B Klein , Laura Horne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 464)
DOI
10.1200/JCO.2018.36.6_suppl.464
Abstract #
464
Poster Bd #
H13
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
First Author: Helen H. Moon
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.
First Author: Melissa Kirker
Poster
2024 ASCO Genitourinary Cancers Symposium
Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Sergio Bracarda
Poster
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.
First Author: Petros Grivas